Professor Shuncheng Li
University of Western Ontario, Canada
Time：2016.1.27 (Wednesday) 9:00 AM
Location: 406 Room, Biotechnology Division, Dalian Institute of Chemical Physics
Introduction：
I. EDUCATION & TRAINING
1995-2000 Postdoctoral Fellow. Lunenfeld-Tanebaum Research Institute, Mount Sinai Hospital,
Toronto. Supervisor: Dr. Tony Pawson.
1995 Ph.D, Univ. of Toronto, Department of Biochemistry. Supervisor: Dr. Charles Deber
1988 MSc, Shanghai Inst. of Biochemistry & Cell Biology, Chinese Academy of Science.
1985 BSc, Department of Chemistry, Beijing University, Beijing.
II. EMPLOYMENT, PROFESSIONAL & SCHOLARLY ACTIVITIES
Academic Positions
2011-present Professor (with tenure), Department of Biochemistry and Department of Oncology, University of Western Ontario (UWO)
2005-2010 Associate Professor (with tenure), Department of Biochemistry, UWO.
2000-2005 Assistant Professor, Department of Biochemistry, Western University
2000-present Senior Scientist, Child Health Research Institute, Lawson Health Research Institute, London, Ontario, Canada
Awards, Honors and Fellowships
2015 Research Excellence Award, Department of Oncology, UWO
2013 Top 10 Research Stories of 2013, Canadian Cancer Society Research Institute
2011-2016 Canada Research Chair in Functional Genomics and Cellular Proteomics (renewal)
2006-2011 Canada Research Chair in Functional Genomics and Cellular Proteomics (Tier II)
2004 Boehringer Ingelheim Young Investigator Award for the Biological Sciences
2004 Dean’s Award of Excellence, Schulich School of Medicine & Dentistry, UWO
2001 Premier’s Research Excellence Award (PREA, Government of Ontario)
2001 Harold E Johns Award. National Cancer Institute of Canada (NCIC).
2001-2007 Research Scientist Award. NCIC
1999-2000 Centennial Fellowship, Medical Research Council of Canada (MRC).
1995-1998 Fellowship, Medical Research Council of Canada.
1995-1998 Fellowship, National Cancer Institute of Canada (NCIC) (declined).
1994 RESTRACOM Award for Scientific Merit, The Hospital for Sick Children, Toronto.
Supervisory Experience (summary)
Postdoctoral Fellows: 28;
Graduate Students: 12;
Undergraduate Students: 20;
Grant and Award Panels
2005 Operating Grants Review Panel Member for CIHR (BMA)
2006-2007 Operating Grants Review Panel Member for NCIC (panel F)
2005-2006 Review Panel member for CIHR RFA projects
2005-2007 Scientific Director, The Foundation for Gene and Cell Therapy, London, Ontario
2007-2008 Grant Reviewer for National Science Foundation, USA.
2009 Fellowship and scholarship Review Panel Member for Canadian Cancer Society
2009 Grant Reviewer for Fondazione Telethon, Italy
2009, 2010 Grant Reviewer for Biomedical Research Council, Singapore
2012 Grant Reviewer, Hongkong University of Science and Technology
2013 Panel Member, Canadian Cancer Society Innovation Grant
2014 Ad Hoc Grant Reviewer, NSERC
2015 Panel Member, Prostate Cancer Canada
2015 Panel Member, Canadian Cancer Society Innovation Grant
Abstract：
Although tremendous advances have been made in the diagnosis and treatment of some forms of cancer following the decoding of the human genome, the initial euphoric predictions that novel disease biomarkers and new drugs would emerge in abundance from large-scale genomic analysis have not yet been realized. This reveals an urgent need for new and innovative strategies for research and drug discovery. In collaboration with the Zou group at Dalian Institute of Chemical Physics, we have developed an innovative technological platform to systematically characterize the cancer phosphoproteome- the full spectrum of proteins that are phosphorylated- with the ultimate goal to identify biomarker candidates for accurate diagnosis and prognosis of cancer. We have discovered a “protein magnet” known as phosphotyrosine- superbinder that binds to proteins phosphorylated on tyrosine, a relatively scarce protein modification associated with cancer initiation, progression and adaptation to therapies. Combining the superbinder with advanced mass spectrometry, we were able to identify protein phosphorylation in a systematic and quantitative manner. Because the superbinder is capable of capturing thousands of phosphoproteins in cancer cells or tissues, the superbinder-based phosphoproteomic strategy may be used to “fingerprint” individual cancers according to the corresponding patterns of protein phosphorylation. This systematic information on protein phosphorylation gleaned from clinical tumour sample analysis may then be used to stratify cancer patients based on drug sensitivity and guide the selection of treatment options.
Contact：1809 Group Lu Wang（9620）